Korro Bio, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Korro Bio, Inc. (KRRO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $31.34 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-15
- Korro Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $29.17M.
- Korro Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- Korro Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- Korro Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $2.16M.
- Korro Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $31.34M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2020-12-31 | $29.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $29.17M derived: sum of 2 quarters · filed 2022-03-15 | $29.17M derived: sum of 3 quarters · filed 2022-03-15 | $31.34M 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $2.16M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.16M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $2.16M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |